Early IVIg may boost myositis recovery
NCT ID NCT05832034
First seen Feb 28, 2026 · Last updated Jun 23, 2026 · Updated 13 times
Summary
This study tests whether adding intravenous immunoglobulin (IVIg) to standard steroid treatment early in myositis helps patients improve faster. It includes 44 adults with recent-onset myositis (less than 12 months). Participants receive either IVIg or a placebo alongside steroids, and improvement is measured after 12 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATOMYOSITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Department of Neurology, Amsterdam UMC, location AMC
Amsterdam, North Holland, 1105 AZ, Netherlands
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Immune Globulin Intravenous (Human) (IVIg)
What this could lead to
If it works, this could mean a faster, more effective way to control myositis early, potentially preventing long-term disability.
What could go wrong
This is a small, early-phase trial (44 participants). The benefit may be modest, and IVIg can cause side effects like headaches or allergic reactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.